Bill Kullback
Independent Director
Bill has served as Chief Financial Officer for Telesis Bio since August 2023. He has over thirty years of experience as a Chief Financial Officer in a broad range of financial management and operational roles, primarily in mid-sized to large corporations, including multiple publicly held life-science companies.
Prior to joining Telesis Bio, Mr. Kullback served for over five years as CFO of BioLegend, Inc., a worldwide provider of life science antibodies and reagents, where he led the company’s September 2021 sale to NYSE listed Revvity (formerly PerkinElmer) for $5.25 billion, the largest acquisition in PerkinElmer’s history. Before joining BioLegend in 2017, Mr. Kullback served as Chief Financial Officer of Lombard Medical, Inc. (Nasdaq: EVAR), a medical device company, from 2014 to 2017, prior to its acquisition by MicroPort Scientific Corporation, a Shanghai, China based medical device group.
Similar prior CFO appointments at other life science and technology companies have resulted in a host of successful transactions involving debt, M&A buy-side, M&A sell-side, and public offerings. Mr.
Kullback earned both his MBA and bachelor’s degree from the State University of New York at Buffalo.
